Videos

Karim Chamie, MD, explains how he might approach immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant settings in the future.

Dr Chamie comments on the significant unmet needs and clinical challenges in the management of MIBC.

Karim Chamie, MD, presents the case of a 77-year-old patient with T2N0M0 MIBC and the potential treatment regimen he would suggest.

Dr Chamie describes how he coordinates with medical oncologists after a referral for MIBC, and his strategies for following up with patients.

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Dr Chamie explains how cisplatin eligibility is defined in patients with MIBC and how many patients in his practice receive neoadjuvant cisplatin therapy.

Karim Chamie, MD, presents the case of a 60-year-old patient with stage 3A muscle-invasive bladder cancer (MIBC) and explains her risk of disease recurrence and whether the case is similar to the patients he typically sees in his clinical practice.

“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.

An overview of the steps involved in the clinical application of mpMRI imaging, from image generation to results interpretation and follow-up.

Dr Gershman discusses how prostate imaging has improved over time, and how and when clinicians implement mpMRI in their practice.

“I think my biggest piece of advice would be to get a social worker into your clinic because there's so many things that we can do,” says Mara Markzon, LCSW, ACM-SW.

A brief commentary on how clinical validity (CV) and clinical utility (CU) are measured for pre-biopsy biomarker tests in patients suspected of having prostate cancer, followed by a focused discussion on the available tests in the space.

Dr Andriole shares insight into how he incorporates pre-biopsy biomarker tests into prostate cancer risk assessment in his clinical practice.

“What we found is that the majority of these companies…offered our ‘secret shopper’ testosterone therapy,” says Joshua A. Halpern, MD, MS.

“First and foremost, it’s great that we have multiple lines of therapy for our bladder cancer patients,” says Tanya Dorff, MD.

Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.

“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.

“It's important to continue to speak up about what we have previously deemed controversial or taboo topics, such as family planning, pay disparities, and discrimination,” says Bridget Lang Findlay, MD.

Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.

Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.

Dr Shore reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.

"It is safe to give 24 hours or less of antibiotics for radical cystectomy. It does not decrease your infectious complications to have extended duration antibiotics," says Megan Prunty, MD.

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

Richard Harris, MD, FACS, provides pointers for young physicians just starting out in the field.

Expert urologist Boris Gershman, MD shares his approach to prostate cancer diagnosis, staging, and risk stratification, highlighting the increasing use of advanced imaging modalities in recent years.